1-{3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl}-1H-benzo[d]imidazol-2(3H)-one | 786613-18-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-{3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl}-1H-benzo[d]imidazol-2(3H)-one
• 英文别名: 1-[3-(4-(2-methoxyphenyl)piperazin-1-yl)propyl]-2,3-dihydro-1H-benzimidazol-2-one；3-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl]-1H-benzimidazol-2-one
• CAS: 786613-18-1
• 化学式: C₂₁H₂₆N₄O₂
• 分子量: 366.463
• InChiKey: YERGVXFJQYPXLJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  48
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-{3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl}-1H-benzo[d]imidazol-2(3H)-one 、 4-甲氧基苯硼酸 在 吡啶-N-氧化物 、 air 、 copper diacetate 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 72.0h， 以40%的产率得到1-(4-methoxyphenyl)-3-[3-(4-(2-methoxyphenyl)piperazin-1-yl)propyl]-1H-benzo[d]imidazol-2(3H)-one
  参考文献：
  名称：

  Benzimidazolone-based serotonin 5-HT1A or 5-HT7R ligands: Synthesis and biological evaluation

  摘要：

  A new group of serotoninergic 5-HT1A or 5-HT7 receptor ligands was identified. These compounds were designed and synthesized on a benzimidazolone scaffold and they enrich the well-known arylpiperazine class of 5-HT ligands. Diverse pharmacomodulations induced a shift in the affinity and selectivity pro. le with final identification of new potent hits. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.02.008
• 作为产物：
  描述：

  1-(2-甲氧苯基)哌嗪 、 3-(3-溴丙基)-2,3-二氢-2-氧代-1H-苯并咪唑-1-羧酸1,1-二甲基乙基酯 在 potassium carbonate 作用下， 以 四氢呋喃 为溶剂， 以82%的产率得到1-{3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl}-1H-benzo[d]imidazol-2(3H)-one
  参考文献：
  名称：

  Benzimidazolone-based serotonin 5-HT1A or 5-HT7R ligands: Synthesis and biological evaluation

  摘要：

  A new group of serotoninergic 5-HT1A or 5-HT7 receptor ligands was identified. These compounds were designed and synthesized on a benzimidazolone scaffold and they enrich the well-known arylpiperazine class of 5-HT ligands. Diverse pharmacomodulations induced a shift in the affinity and selectivity pro. le with final identification of new potent hits. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.02.008

文献信息

• [EN] BENZIMIDAZOLONE DERIVATIVES AS 5-HT1A AND 5-HT2 ANTAGONISTS
  申请人：BOEHRINGER INGELHEIM ITALIA S.P.A.

  公开号：WO1993003016A1

  公开（公告）日：1993-02-18

  (EN) Pharmacologically active benzimidazolone derivatives as 5-HT1A and 5-HT2 receptors, useful in the treatment of CNS disorders of formula (I), wherein R1 and R2 may be at the same time or not a hydrogen atom, halogen, trifluoromethyl, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C1-6 acyl, carboxyl, C1-6 alkoxy- carbonyl, hydroxy, nitro, amino optionally C1-4 alkyl N-mono or di-substituted, C1-6 acylamino, C1-6 alkoxycarbonylamino, carbamoyl optionally C1-4 alkyl N-mono or di-substituted, cyano, C1-6 alkylsulphinyl, C1-6 alkylsulphonyl, amino sulphonyl optionally C1-4 alkyl N-mono or di-substituted, C1-4 alkyl N-mono or di-substituted aminosulphonylamino, aminosulphonylamino; R3 is hydrogen, C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl; A is -CO- or -CONH- or it is absent; B is a straight or branched, saturated or unsaturated C2-6 alkyl; m and n are both independently an integer from 1 to 3; R4 is an aryl, aralkyl, a heteroaryl, or heteroaralkyl group, each group being optionally substituted by one or more substituents selected from halogen, trifluoromethyl, cyano, C1-3 alkoxy, C1-4 alkyl and acid addition salts thereof. The process for the preparation of the compounds of formula (I) as well as pharmaceutical compositions containing them are also described.(FR) Dérivés pharmacologiquement actifs de benzimidazolone servant de récepteurs de 5-HT1A et de 5-HT2 et utiles dans le traitement des troubles du système nerveux central. Ils répondent à la formule (I), dans laquelle R1 et R2 sont identiques ou différents et représentent un atome d'hydrogène, halogène, trifluorométhyle, alkyle C1-6, alcoxy C1-6, alkylthio C1-6, acyle C1-6, carboxyle, alcoxy C1-6 -carbonyle, hydroxy, nitro, amino éventuellement N-monosubstitué ou disubstitué par alkyle C1-4, acylamino C1-6, alcoxycarbonylamino C1-6, carbamoyle éventuellement N-monosubstitué ou disubstitué par alkyle C1-4, alkylsufinyle C1-6, alkylsulfonyle C1-6, aminosulfonyle éventuellement N-mono ou disubstitué par alkyle C1-4, aminosulfonylamino N-mono ou disubstitué par alkyle C1-4, ou aminosulfonylamino; R3 représente hydrogène, alkyle C1-6, alcényle C2-6, ou alcynyle C2-6; A représente -CO- ou -CONH- ou est absent; B représente alkyle C2-6 linéaire ou ramifié et saturé ou insaturé; m et n, indépendamment l'un de l'autre, représentent un nombre entier compris entre 1 et 3; R4 représente un groupe aryle, aralkyle, hétéroaryle ou hétéroaralkyle, chaque groupe étant éventuellement substitué par un ou plusieurs substituant sélectionnés parmi halogène, trifluorométhyle, cyano, alcoxy C1-3, alkyl C1-4, et leurs sels d'addition d'acide. On a également prévu un procédé de préparation des composés de la formule (I), ainsi que des compositions pharmaceutiques les contenant.

  具有药理活性的苯并咪唑酮衍生物作为5-HT1A和5-HT2受体，在治疗公式（I）中的中枢神经系统疾病中有用，其中R1和R2可以同时也可以不是氢原子，卤素，三氟甲基，C1-6烷基，C1-6烷氧基，C1-6烷硫基，C1-6酰基，羧基，C1-6烷氧基-羰基，羟基，硝基，氨基可选C1-4烷基N-单或双取代，C1-6酰基氨基，C1-6烷氧羰基氨基，氨基甲酰基可选C1-4烷基N-单或双取代，氰基，C1-6烷基磺酰基，C1-6烷基磺酰基，氨基磺酰基可选C1-4烷基N-单或双取代，C1-4烷基N-单或双取代氨基磺酰氨基，氨基磺酰氨基；R3是氢，C1-6烷基，C2-6烯基或C2-6炔基；A是-CO-或-CONH-或不存在；B是直链或支链，饱和或不饱和的C2-6烷基；m和n都是独立的1到3的整数；R4是芳基，芳基烷基，杂芳基或杂芳基烷基基团，每个基团都可以选择地被一个或多个取代基取代，所述取代基被选择自卤素，三氟甲基，氰基，C1-3烷氧基，C1-4烷基和它们的酸加成盐。还描述了制备公式（I）化合物的过程以及含有它们的制药组合物。
• Benzimidazolone derivatives as 5-HT1A and 5-HT2 antagonists
  申请人：BOEHRINGER INGELHEIM ITALIA S.p.A.

  公开号：EP0526434B1

  公开（公告）日：2000-04-19
• US5576318A
  申请人：——

  公开号：US5576318A

  公开（公告）日：1996-11-19
• Benzimidazolone-based serotonin 5-HT1A or 5-HT7R ligands: Synthesis and biological evaluation
  作者：Eduard Badarau、Franck Suzenet、Andrzej J. Bojarski、Adriana-Luminiţa Fînaru、Gérald Guillaumet

  DOI：10.1016/j.bmcl.2009.02.008

  日期：2009.3

  A new group of serotoninergic 5-HT1A or 5-HT7 receptor ligands was identified. These compounds were designed and synthesized on a benzimidazolone scaffold and they enrich the well-known arylpiperazine class of 5-HT ligands. Diverse pharmacomodulations induced a shift in the affinity and selectivity pro. le with final identification of new potent hits. (C) 2009 Elsevier Ltd. All rights reserved.